

Applicants: Douglas J. M. Allen et al.
Serial No.: 10/716,098
Filed : November 17, 2003
Page 2

In the Claims

Please cancel claims 14-15 without prejudice to applicants' right to pursue the subject matter of these claims in this or a subsequent application.

1. - 11. (Canceled)

12. (Previously Presented): N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate.

13. (Previously Presented): A hydrate form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate of claim 12.

14 - 15. (Cancelled)

16. (Currently Amended): ~~The~~^A pharmaceutical composition of ~~claim 15,~~ comprising from about 0.001 mg to about 100 mg of ~~the compound~~ N-(ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate and a pharmaceutically acceptable carrier.

17. (Previously Presented): The pharmaceutical composition of claim 16, comprising from about 1 mg to about 35 mg of the compound.

18. (Previously Presented): The pharmaceutical composition of claim 16, comprising from about 0.05 mg to about 7 g of the compound.

Applicants: Douglas J. M. Allen et al.
Serial No.: 10/716,098
Filed : November 17, 2003
Page 3

19.(Previously Presented): The pharmaceutical composition of claim 17, comprising from about 0.2 g to about 2.5 g of the compound.

20.(Previously Presented): The pharmaceutical composition of claim 19, in the form of a tablet, capsule, pill, powder, sustained release formulations, solution, parenteral injection as a sterile solution, suspension or emulsion, or suppository.

21.(Previously Presented): The pharmaceutical composition of claim 20, in the form of a parenteral injection.

22.(Previously Presented): The pharmaceutical composition of claim 20, in the form of a tablet.

23.(Currently Amended): A method of treating a mammal suffering from a hyperproliferative disorder which comprises administering to said mammal an amount of the ~~compound~~pharmaceutical composition of claim ~~12~~
~~16~~ therapeutically effective to inhibit the epidermal growth factor receptor ("EGFR") in the mammal, so as to thereby treat the mammal.

24.(Previously Presented): The method of claim 23 wherein the hyperproliferative disorder is a cancer selected from the group consisting of brain, lung, squamous cell, bladder, gastric, pancreatic, breast, head, neck, renal, kidney, ovarian, prostate, colorectal, oesophageal, gynecological and thyroid cancer.

Applicants: Douglas J. M. Allen et al.
Serial No.: 10/716,098
Filed : November 17, 2003
Page 4

25. (Currently Amended): The method of claim 23 further comprising administering to said mammal a therapeutically effective amount of a compound selected from the group consisting of ~~mitotic inhibitors~~, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell-cycle inhibitor, enzymes, topoisomerase, inhibitors, ~~biological response modifiers~~, anti-hormones, and anti-androgens.

26. (New): The method of claim 25 wherein the cell-cycle inhibitor is a mitotic inhibitor.